TEM vs BMY
diagnostics · Bristol-Myers Squibb
| TEM diagnostics Healthcare | BMY Bristol-Myers Squibb Healthcare | |
|---|---|---|
| Market | ||
| Price | $81.52 +3.87% | $62.98 -0.06% |
| Market cap | $13.2B | $128.0B |
| P/E (TTM) | — | 13.8 |
| Dividend yield | — | 4.58% |
| 52-week range | $40.77 – $91.83 | $43.20 – $68.64 |
| Our research | ||
| Our view | LONG open | LONG open |
| Articles | 1 | 1 |
| Latest article | Tempus Grew Revenue 23%, But A $42.8 Million Securities Gain Helped The Loss Nov 3, 2026 | Bristol-Myers Squibb: The Forensic Case That The Patent Cliff Math Has Already Been Solved May 27, 2026 |
| Latest earnings | ||
| Reported | — | Oct 29, 2026 |
| Revenue | — | $13.1 billion +7% YoY |
| EPS | — | $1.05 |
| Guidance | — | Guidance raised |
| Revenue growth, last 4 reports | — | +7% |
| Topics | ||
| Main topics | ||
| Company page | Company page · Earnings releases | |
Note. Earnings figures are extracted automatically from each company's own release; prices are delayed up to 15 minutes. This comparison is information, not investment advice.